← board
ADPT
distress 1/10 · well-funded / low risk$22.36+2%today-2% from 52w high
Revenue
$71M
Liquidity
$78M
Runway
2.9 yrs
Shares 1y
+5%
Price & events
+17.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.9%
1D
+1.2%
1W
+29.8%
1M
+61.8%
3M
+20.5%
6M
+105.7%
1Y
+432.4%
2Y
-42.3%
5Y
-59.9%
All
Overview
- Market Cap
- $3.58B
- Enterprise Value
- $3.63B
- Volume
- 187.81K
- 52 Week Range
- $10.24 – $22.92
- Total Shares
- 160.04M
- Float Shares
- 125.59M
- Short %
- 35.83%
- % Held by Insiders
- 1.84%
- % Held by Institutions
- 96.60%
- RVOL
- 0.05x
- Beta
- 2.07
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-07-29Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $22 (-2% upside) · 7 analysts
- 2026-07-09Morgan StanleyEqual-Weight
- 2026-06-29GuggenheimBuy
- 2026-06-17BTIGBuy
- 2026-05-12Morgan StanleyEqual-Weight
- 2026-05-06TD CowenBuy
- 2026-05-06JP MorganOverweight
Competitors
- none identified
Recent news
- 2026-07-21ADPT (ADPT) Form 144 shows Harlan Robins planning sizable stock sale - Stock Titan
- 2026-07-21Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Amidst Valuation Challenges - DirectorsTalk Interviews
- 2026-07-21Form 4 Adaptive Biotechnologies Corp For: 21 July By Investing.com - Investing.com Nigeria
- 2026-07-20Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells 5,000 shares in plan - Stock Titan
- 2026-07-18Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com - Investing.com Canada
- 2026-07-18Adaptive Biotechnologies CPO Lo reports $2.39m stock sale - Investing.com
- 2026-07-17Form 4 Adaptive Biotechnologies Corp For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Adaptive Biotechnologies Corp (ADPT) officer exercises 105,762 options and sells 105,762 shares - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.